BIOTECHNOLOGYU.S. Plans to Boost US Biotechnology Manufacturing
The administration announced Monday steps to bolster the “bioeconomy” in the United States, a classification that covers research and development across a broad swath of products, including medical supplies, sustainable new fuels and food, as well as technologies meant to help fight climate change. The order comes barely a month after President Biden signed a major piece of legislation, the CHIPS Act, meant to supercharge U.S. manufacturing of semiconductors, an area in which the U.S. has lost its once-dominant global position.
In an executive order signed Monday, President Joe Biden announced steps by his administration to bolster the “bioeconomy” in the United States, a classification that covers research and development across a broad swath of products, including medical supplies, sustainable new fuels and food, as well as technologies meant to help fight climate change.
The order comes barely a month after Biden signed a major piece of legislation, the CHIPS Act, meant to supercharge U.S. manufacturing of semiconductors, an area in which the U.S. has lost its once-dominant global position.
The effort to boost the U.S. biotech sector further underscores the administration’s apparent belief that deeper engagement by the federal government with domestic manufacturing operations is necessary to preserve U.S. competitiveness in the global economy.
In a briefing over the weekend, administration officials made it clear that the administration’s push to bring more U.S.-based biotechnology manufacturing online comes as a response to other countries — particularly China — investing heavily in the sector.
Administration officials stressed that biotechnology-based products and “biomanufacturing” present a promising alternative to many current products — fuel, plastics and other materials — that are currently made using the byproducts of carbon-laden petrochemicals.
Order Text
The executive order reads, in part, “It is the policy of my Administration to coordinate a whole-of-government approach to advance biotechnology and biomanufacturing towards innovative solutions in health, climate change, energy, food security, agriculture, supply chain resilience, and national and economic security.”
It continues, “Central to this policy and its outcomes are principles of equity, ethics, safety, and security that enable access to technologies, processes, and products in a manner that benefits all Americans and the global community and that maintains United States technological leadership and economic competitiveness.”
Caution Urged
Among the Biden administration’s promises in the executive order is a vow to “substitute fragile supply chains from abroad with strong chains at home.” But not everyone agrees that a government effort to manipulate the supply chain is the smartest strategy for the long run.
“Government can play a role in funding basic research, university labs and the rest, but when it starts micromanaging supply chains, you end up with more fragile supply chains than robust ones,” Scott Lincicome, a director for general economics and trade at the Libertarian-leaning Cato Institute, told VOA.
Similarly, he said, government decisions to privilege “onshore” production over foreign producers can be dangerous.
